UK & European Patent Attorney
BSc, PhD, Certificate In IP Law, EPA, CPA
David joined Mathys & Squire after working for another private practice intellectual property firm. He has a background in biochemistry. He acts for UK and overseas biotechnology, pharmaceutical, and food/beverage clients, as well as SMEs and academic institutions in all patent matters. David has been ranked as a ‘Notable Practitioner’ in the 2020 edition of Managing IP’s IP STARS directory.
David has extensive patent drafting and multi-jurisdictional prosecution experience. He is also experienced at providing therapeutic freedom to operate and validity advice, as well as handling opposition proceedings before the EPO. Some key hearings include: “Recombinant EPO” (Sterrenbeld Biotechnologie; Polymun Scientific Immunbiologische) and “Modified Clostridial Neurotoxins” (Ipsen Bioinnovation; Merz Pharma).Building on his in-depth knowledge of biochemistry much of the patent work he performs relates to enzyme biotechnology, including its application in the food and pharmaceutical industries, as well as antibody therapeutics and plant biotechnology.
David has a PhD in Biochemistry from the Cancer Research UK London Research Institute (awarded by UCL). His PhD was in the field of transcription and enzyme mechanisms, specifically. Click here for more information.
Memberships & organisations
David is a European Patent Attorney, Chartered UK Patent Attorney, EPI Member and a Fellow of the Chartered Institute of Patent Attorney
David has co-authored a number of publications and a link to these publications is below.
The Nagoya Protocol – A Practical Overview, Thomas Bjørn & David Hobson, Copenhagen Life Science (September/October 2015)
When is it Health Data and When is it Not?, Thomas Bjørn & David Hobson, Copenhagen Life Science (July/August 2015)
Food & beverage
Life sciences & chemistry
Subscribe to our mailing list to receive our monthly newsletter which includes the latest news and industry insights.
Please select your areas of interest: